Erdem Cig

Dr. Erdem Cig

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2026 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
EKEnes Karakaya
Enes Karakaya
ECErdem Cig
Erdem Cig
BSBurcu Saka
Burcu Saka
HKHilal Kağızmanlı
Hilal Kağızmanlı
CSCopur Sidar
Copur Sidar
GGGenco Gencdal
Genco Gencdal
Immune checkpoint inhibitor therapy has transformed the prognosis of multiple solid-organ malignancies; however, such advances are not without significant adverse events known as immune-related adverse events. A novel pattern of autoimmune-like hepatitis following exposure to certain medications, including statins, isoniazid, nitrofurantoin, anti-tumor necrosis factor-alpha therapy and minocycline, has recently been recognized. We present the case of a 66-year-old male patient with extensive-stage small-cell lung carcinoma who developed acute liver injury while receiving concomitant atezolizumab therapy and isoniazid prophylaxis for latent tuberculosis. The patient subsequently developed grade 4 hepatotoxicity, which improved after discontinuation of isoniazid therapy and initiation of corticosteroid treatment. The aim of this report is to contribute to the literature by presenting a rare case of grade 4 immune-related hepatotoxicity under atezolizumab therapy in a patient receiving isoniazid prophylaxis for latent tuberculosis.

26 August 2025 in LLM Dergi
Verified
Journal Article
Closed access
TTTaner Tan
Taner Tan
ATAhmet Umur Topcu
Ahmet Umur Topcu
ECErdem Cig
Erdem Cig
ESEfe Semercioğlu
Efe Semercioğlu
EOEmre Osmanbaşoğlu
Emre Osmanbaşoğlu
SBSinem Civriz Civriz Bozdag
Sinem Civriz Civriz Bozdag

10 June 2026 in Vascular Medicine
Verified
Journal Article
Closed access
TTTaner Tan
Taner Tan
UTUmur Topçu
Umur Topçu
ECErdem Cig
Erdem Cig
OAOlga Meltem Akay
Olga Meltem Akay

1 August 2026 in The European Research Journal
Verified
Journal Article
Open access
PDF file
ZAZeynep Atceken
Zeynep Atceken
ECErdem Cig
Erdem Cig
Yuksel PekerYuksel Peker
Yuksel Peker
TTTaner Tan
Taner Tan
Objective: To investigate clinical determinants of mediastinal lymph node attenuation (MLNA) on non-contrast chest computed tomography (CT), focusing on smoking history and cardiometabolic factors. Methods: In this retrospective single-center study, individuals undergoing non-contrast chest CT without known cardiopulmonary disease were included. MLNA was measured in Hounsfield units (HU) from the largest visible mediastinal lymph node. Smoking status (ever vs never), age, sex, hypertension, diabetes mellitus, and body mass index were recorded. Multivariable linear regression identified independent predictors of MLNA. Receiver operating characteristic (ROC) analysis evaluated attenuation for discriminating smoking history. Results: A total of 138 individuals were analyzed (82 ever smokers, 56 never smokers). MLNA was higher in ever smokers than never smokers (median 39.5 vs 35 HU, P=0.001). In multivariable analysis, smoking history remained independently associated with increased attenuation (B=5.48 HU, 95% confidence interval [CI]: 1.72–9.23, P=0.005). Age (B=0.33 HU/year, P<0.001), hypertension (B=6.55 HU, P=0.009), and diabetes mellitus (B=5.93 HU, P=0.043) were also independent predictors, whereas sex and BMI were not significant. The model explained 41% of attenuation variance (R²=0.41). ROC analysis demonstrated moderate discrimination for smoking history (area under curve [AUC] = 0.66; optimal cut-off 46 HU, specificity of 89.3%). Attenuation values were highest among current smokers in exploratory analyses. Conclusion: Smoking history, age, hypertension, and diabetes mellitus are independently associated with increased mediastinal lymph node attenuation on non-contrast CT. Elevated attenuation may reflect chronic inflammatory activation, fibrotic remodeling, and cumulative cardiometabolic tissue injury rather than overt pathology, supporting its role as a contextual imaging marker in risk-aware radiologic interpretation.

6 November 2026 in Medicina
Verified
Journal Article
Open access
PDF file
TTTaner Tan
Taner Tan
ZAZeynep Atceken
Zeynep Atceken
ESEfe Semercioğlu
Efe Semercioğlu
ECErdem Cig
Erdem Cig
ATAhmet Umur Topçu
Ahmet Umur Topçu
SBSinem Civriz Bozdağ
Sinem Civriz Bozdağ
Background and Objectives: Autologous hematopoietic stem cell transplantation (AHSCT) can lead to skeletal muscle loss owing to the catabolic state and inflammatory burden it induces. Pectoral muscle density (PMD), measured on thoracic CT, is a valuable indicator for assessing muscle composition and quality. However, its time-dependent change during AHSCT and the early post-transplant period, as well as its prognostic value, remain insufficiently defined. This study evaluated the dynamic changes in PMD following AHSCT and the clinical relevance of pre-transplant PMD. Materials and Methods: This single-center retrospective study included patients who underwent AHSCT between January 2022 and December 2024 and had a pre-transplant thoracic CT scan available. Patients with both pre- and post-transplant thoracic CT images constituted the longitudinal subgroup in which the dynamic change in PMD was assessed. PMD was measured in Hounsfield units (HU) on non-contrast CT, on a single axial slice immediately above the aortic arch using a 1-cm2 region of interest, taking the average of three measurements. The primary endpoint was the change in PMD between the pre- and post-transplant scans; secondary endpoints were length of hospital stay, neutrophil and platelet engraftment, and overall survival. Paired t-tests, Wilcoxon signed-rank and Mann–Whitney U tests, Spearman correlation, multivariable linear regression, and Cox proportional hazards and Kaplan–Meier analyses were used. Results: 142 patients (57.0% male; mean age 53.5 ± 14.9 years; multiple myeloma 43.7%, non-Hodgkin lymphoma 38.0%, Hodgkin lymphoma 14.1%) were analyzed; mean pre-transplant PMD was 52.95 ± 9.66 HU. In the longitudinal subgroup (n = 79; post-transplant CT at a median of day +12), PMD declined in 96.2% of patients, from 52.80 ± 9.22 to 41.99 ± 9.21 HU (mean reduction 10.81 HU; 95% CI 9.19–12.43; p < 0.001; Cohen’s dz = 1.50; mean change −20.27 ± 13.36%). The decline was independent of the inter-scan interval, sex, age, and diagnosis. Lower PMD correlated with older age (ρ = −0.281, p < 0.001) and differed by underlying diagnosis (p = 0.022). Patients with pre-transplant PMD ≤ 60 HU had a longer mean hospital stay than those with PMD > 60 HU (19.6 vs. 16.4 days); however, this difference was not significant in non-parametric (p = 0.33) or multivariable analyses (p = 0.25). Baseline PMD was not significantly associated with engraftment or overall survival (HR per 10-HU decrease 1.35; 95% CI 0.91–2.00; p = 0.14). Conclusions: A marked and consistent decline in pectoral muscle density occurs in the early period following AHSCT, irrespective of scan timing, sex, age, or diagnosis. Baseline PMD was not significantly associated with engraftment, hospitalization, or survival, although numerical trends toward longer hospitalization and poorer survival were observed with lower PMD. PMD, obtainable from routine non-contrast thoracic CT, may serve as a marker of transplant-related changes in muscle quality, and its prognostic value warrants prospective evaluation.